Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Review ArticleVolume 4 Issue 10

Inflammatory Bowel Disease in the Elderly in the Context of COVID-19. What do we know so?

Carlos Henrique Rodrigues Castro1,2*, Caroline Rodrigues Castro1, Jackson Santos dos Reis1,2, Ewerton Naves Dias1, Claudio Roberto Tavares Pereira3, Camila Neto da Silveira4 and Luiz Ronaldo Alberti5

1Postgraduate Program in Professional Degree in Psychogerontology, Educatie School, Brazil
2Technical School Educare, Brazil
3Clinimage, Image Clinic, Brazil
4OSID - The Charitable Works Foundation of Sister Dulce, Brazil
5PhD. MSc. Doctor in Medicine, School of Medicine, Department of Surgery, Federal University of Minas Gerais, Brazil

*Corresponding Author: Carlos Henrique Rodrigues Castro, Department of Gerontology, Postgraduate Program in Professional Degree in Psychogerontology, Educatie School, Brazil.

Received: August 25, 2021; Published: September 08, 2021

Citation: Carlos Henrique Rodrigues Castro., et al. “Inflammatory Bowel Disease in the Elderly in the Context of COVID-19. What do we know so?". Acta Scientific Gastrointestinal Disorders 4.10 (2021): 09-12.


  Over the last few decades, several authors have demonstrated the relationship of the interaction of the immune system in a pathway called the “gut-brain axis,” with implications both for the local immune response and for the systemic modulation of inflammatory mediators. The hypothesis that the underlying inflammatory disease contributes to the pathogenesis of SARS-CoV-2, and consequently patients with inflammatory bowel disease (IBD) may theoretically be at increased risk of infection and mortality, is still controversial. With the increase in the diagnosis of IBD in patients over 60 years of age, the increased concern in the context of the SARS-CoV-2 pandemic was evident, as elderly patients have comorbidities that could raise the risk of worsening the progression of the infection and unfavorable clinical outcomes. Thus, a survey of the literature to date was carried out to understand the implications of IBD in the context of the SARS-CoV-2 pandemic.

Keywords: Elderly; Inflammatory Bowel Disease; SARS-CoV-2; COVID-19


  1. Collaborators GBDIBD. “The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017”. The Lancet Gastroenterology and Hepatology1 (2020): 17-30.
  2. Mak WY., et al. “The epidemiology of inflammatory bowel disease: East meets west”. Journal of Gastroenterology and Hepatology3 (2020): 380-389.
  3. Rozich JJ., et al. “Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease”. Inflammatory Bowel Disease8 (2021): 1215-1223.
  4. De Jong ME., et al. “Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients”. Journal of Crohn's and Colitis7 (2020): 888-895.
  5. Taxonera C., et al. “2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases”. Alimentary Pharmacology and Therapeutics2 (2020): 276-283.
  6. Attauabi M., et al. “Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study”. Journal of Crohn's and Colitis4 (2021): 540-550.
  7. Calafat M., et al. “Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease”. Aging Clinical and Experimental Research8 (2021): 2355-2359.
  8. Kjeldsen J., et al. “Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark”. Journal of Autoimmunity 120 (2021): 102632.
  9. Potdar AA., et al. “Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease”. Gastroenterology 3 (2021): 809-822.
  10. Maconi G., et al. “Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population”. Digestive and Liver Disease 3 (2021): 263-270.
  11. Scharrer S., et al. “Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease”. European Journal of Gastroenterology and Hepatology 3 (2021): 443-447.
  12. Willows S., et al. “A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis”. Biochemistry and Cell Biology 2 (2021): 173-194.
  13. Xu F., et al. “COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020”. Inflammatory Bowel Disease7 (2021): 1166-1169.
  14. Neurath MF. “COVID-19 and immunomodulation in IBD”. Gut7 (2020): 1335-1342.
  15. Mak JWY., et al. “Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry”. Journal of Crohn's and Colitis3 (2021): 401-408.
  16. Suarez-Farinas M., et al. “Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease”. Gastroenterology1 (2021): 287-301.
  17. Fernandez Alvarez P., et al. “Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results”. Revista Espanola de Enfermedades Digestivas2 (2021): 92-97.
  18. Berte R., et al. “Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy”. Journal of Crohn's and Colitis5 (2021): 864-868.
  19. Piovani D., et al. “Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease”. Alimentary Pharmacology and Therapeutics9 (2020): 820-830.
  20. Khan N., et al. “Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis”. Inflammatory Bowel Diseases3 (2020): 462-468.
  21. Kennedy NA., et al. “Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab”. Gut5 (2021): 865-875.
  22. Mak JWY., et al. “Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan”. Journal of Gastroenterology and Hepatology1 (2021): 171-173.
  23. Kuenzig ME., et al. “Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study”. The Journal of the Canadian Association of Gastroenterology2 (2021): e16-e30.
  24. Moum KM., et al. “Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic”. Scandinavian Journal of Gastroenterology5 (2021): 545-551.

Copyright: © Carlos Henrique Rodrigues Castro., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US